• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Convalescent plasma and remdesivir for protracted COVID-19 in a patient with chronic lymphocytic leukaemia: a case report of late relapse after rapid initial response.

作者信息

Schenker Carla, Hirzel Cédric, Walti Laura N, Zeerleder Sacha S, Andres Martin, Ramette Alban, Barbani Maria T, Suter-Riniker Franziska, Holbro Andreas, Tritschler Tobias

机构信息

Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.

Department of Infectious Disease, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.

出版信息

Br J Haematol. 2022 Feb;196(3):e27-e29. doi: 10.1111/bjh.17806. Epub 2021 Aug 30.

DOI:10.1111/bjh.17806
PMID:34458995
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8652702/
Abstract
摘要

相似文献

1
Convalescent plasma and remdesivir for protracted COVID-19 in a patient with chronic lymphocytic leukaemia: a case report of late relapse after rapid initial response.慢性淋巴细胞白血病患者长期新冠病毒肺炎的恢复期血浆和瑞德西韦治疗：快速初始反应后晚期复发的病例报告
Br J Haematol. 2022 Feb;196(3):e27-e29. doi: 10.1111/bjh.17806. Epub 2021 Aug 30.
2
Sustained Response After Remdesivir and Convalescent Plasma Therapy in a B-Cell-Depleted Patient With Protracted Coronavirus Disease 2019 (COVID-19).B 细胞耗竭患者接受瑞德西韦和恢复期血浆治疗后持续缓解新冠肺炎（COVID-19）。
Clin Infect Dis. 2021 Dec 6;73(11):e4020-e4024. doi: 10.1093/cid/ciaa1637.
3
Dramatic Response to Convalescent Hyperimmune Plasma in Association With an Extended Course of Remdesivir in 4 B Cell-Depleted Non-Hodgkin Lymphoma Patients With SARS-Cov-2 Pneumonia After Rituximab Therapy.4 例利妥昔单抗治疗后并发 SARS-CoV-2 肺炎的 B 细胞耗竭性非霍奇金淋巴瘤患者接受瑞德西韦延长疗程治疗的同时输注恢复期高免疫血浆，获得显著疗效。
Clin Lymphoma Myeloma Leuk. 2021 Sep;21(9):e731-e735. doi: 10.1016/j.clml.2021.05.013. Epub 2021 May 21.
4
Emerging RNA-Dependent RNA Polymerase Mutation in a Remdesivir-Treated B-cell Immunodeficient Patient With Protracted Coronavirus Disease 2019.在接受瑞德西韦治疗的 B 细胞免疫缺陷的 COVID-19 患者中出现的新的依赖 RNA 的 RNA 聚合酶突变。
Clin Infect Dis. 2021 Oct 5;73(7):e1762-e1765. doi: 10.1093/cid/ciaa1474.
5
Successful early treatment combining remdesivir with high-titer convalescent plasma among COVID-19-infected hematological patients.瑞德西韦与高滴度康复期血浆联合用于COVID-19感染血液病患者的早期治疗取得成功。
Hematol Oncol. 2021 Dec;39(5):715-720. doi: 10.1002/hon.2908. Epub 2021 Aug 16.
6
Early administration of remdesivir plus convalescent plasma therapy is effective to treat COVID-19 pneumonia in B-cell depleted patients with hematological malignancies.早期使用瑞德西韦联合恢复期血浆疗法对 B 细胞耗竭的血液恶性肿瘤 COVID-19 肺炎患者有效。
Ann Hematol. 2022 Oct;101(10):2337-2345. doi: 10.1007/s00277-022-04924-6. Epub 2022 Jul 14.
7
Severe Acute Respiratory Syndrome Coronavirus-2 Pneumonia in a Newborn Treated With Remdesivir and Coronavirus Disease 2019 Convalescent Plasma.瑞德西韦和 2019 冠状病毒病恢复期血浆治疗的新生儿重症急性呼吸综合征冠状病毒 2 型肺炎。
J Pediatric Infect Dis Soc. 2021 May 28;10(5):691-694. doi: 10.1093/jpids/piaa165.
8
A Patient with X-Linked Agammaglobulinemia and COVID-19 Infection Treated with Remdesivir and Convalescent Plasma.一名患有X连锁无丙种球蛋白血症且感染新冠病毒的患者接受瑞德西韦和康复期血浆治疗。
J Clin Immunol. 2021 Jul;41(5):923-925. doi: 10.1007/s10875-021-00983-y. Epub 2021 Feb 6.
9
Clearance of the SARS-CoV-2 Virus in an Immunocompromised Patient Mediated by Convalescent Plasma without B-Cell Recovery.免疫功能低下患者的恢复期血浆介导的 SARS-CoV-2 病毒清除，无 B 细胞恢复。
Int J Mol Sci. 2021 Aug 18;22(16):8902. doi: 10.3390/ijms22168902.
10
Extended remdesivir administration in haematological patients with malignancies and COVID-19 during the Omicron era: safety and outcomes.奥密克戎时代血液系统恶性肿瘤合并 COVID-19 患者延长使用瑞德西韦：安全性和结局。
J Antimicrob Chemother. 2024 Sep 3;79(9):2364-2368. doi: 10.1093/jac/dkae237.

引用本文的文献

1
Safety and Efficacy of Convalescent Plasma Combined with Other Pharmaceutical Agents for Treatment of COVID-19 in Hospitalized Patients: A Systematic Review and Meta-Analysis.恢复期血浆联合其他药物治疗住院COVID-19患者的安全性和有效性：系统评价与Meta分析
Diseases. 2024 Feb 21;12(3):41. doi: 10.3390/diseases12030041.
2
COVID-19 Convalescent Plasma for the Treatment of Immunocompromised Patients: A Systematic Review and Meta-analysis.COVID-19 恢复期血浆治疗免疫功能低下患者：系统评价和荟萃分析。
JAMA Netw Open. 2023 Jan 3;6(1):e2250647. doi: 10.1001/jamanetworkopen.2022.50647.
3
Persistent SARS-CoV-2 infection in immunocompromised patients facilitates rapid viral evolution: Retrospective cohort study and literature review.免疫功能低下患者中持续的SARS-CoV-2感染促进病毒快速进化：回顾性队列研究与文献综述
Clin Infect Pract. 2022 Nov;16:100210. doi: 10.1016/j.clinpr.2022.100210. Epub 2022 Nov 16.
4
Early administration of remdesivir plus convalescent plasma therapy is effective to treat COVID-19 pneumonia in B-cell depleted patients with hematological malignancies.早期使用瑞德西韦联合恢复期血浆疗法对 B 细胞耗竭的血液恶性肿瘤 COVID-19 肺炎患者有效。
Ann Hematol. 2022 Oct;101(10):2337-2345. doi: 10.1007/s00277-022-04924-6. Epub 2022 Jul 14.

本文引用的文献

1
A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia.新冠肺炎重症肺炎患者恢复期血浆的随机临床试验。
N Engl J Med. 2021 Feb 18;384(7):619-629. doi: 10.1056/NEJMoa2031304. Epub 2020 Nov 24.
2
Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial).恢复期血浆治疗印度成人中度 COVID-19 的管理：开放标签 II 期多中心随机对照试验（PLACID 试验）。
BMJ. 2020 Oct 22;371:m3939. doi: 10.1136/bmj.m3939.
3
Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19.COVID-19 病程延长的 B 细胞耗竭患者的恢复期血浆治疗。
Blood. 2020 Nov 12;136(20):2290-2295. doi: 10.1182/blood.2020008423.
4
Persistent COVID-19 in an Immunocompromised Patient Temporarily Responsive to Two Courses of Remdesivir Therapy.免疫功能低下患者持续性 COVID-19 经瑞德西韦两疗程治疗暂时起效
J Infect Dis. 2020 Sep 1;222(7):1103-1107. doi: 10.1093/infdis/jiaa446.
5
Discovery and Genomic Characterization of a 382-Nucleotide Deletion in ORF7b and ORF8 during the Early Evolution of SARS-CoV-2.在 SARS-CoV-2 的早期进化过程中发现并鉴定了 ORF7b 和 ORF8 中 382 个核苷酸的缺失。
mBio. 2020 Jul 21;11(4):e01610-20. doi: 10.1128/mBio.01610-20.
6
Outcomes of COVID-19 in patients with CLL: a multicenter international experience.慢性淋巴细胞白血病患者感染新型冠状病毒肺炎的结局：一项多中心国际经验
Blood. 2020 Sep 3;136(10):1134-1143. doi: 10.1182/blood.2020006965.
7
Clinical outcomes and risk factors for severe COVID-19 in patients with haematological disorders receiving chemo- or immunotherapy.接受化疗或免疫治疗的血液系统疾病患者发生重症 COVID-19 的临床结局和危险因素。
Br J Haematol. 2020 Oct;191(2):194-206. doi: 10.1111/bjh.17027. Epub 2020 Aug 12.
8
Convalescent plasma for persisting COVID-19 following therapeutic lymphocyte depletion: a report of rapid recovery.治疗性淋巴细胞清除后用于持续性新冠病毒肺炎的康复期血浆：快速康复报告
Br J Haematol. 2020 Aug;190(3):e154-e156. doi: 10.1111/bjh.16981. Epub 2020 Jul 16.
9
Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial.恢复期血浆疗法对重症和危及生命的 COVID-19 患者临床改善时间的影响：一项随机临床试验。
JAMA. 2020 Aug 4;324(5):460-470. doi: 10.1001/jama.2020.10044.